Patrick G. Harran - Dallas TX, US Jing Li - Dallas TX, US Susan Jeong - Dallas TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61P 35/00 A61K 31/42 A61K 31/425 C07D 487/00
US Classification:
514366, 514375, 540457
Abstract:
The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.
Zhenkun Ma - Dallas TX, US In Ho Kim - Lewisville TX, US Jing Li - Dallas TX, US
Assignee:
Cumbre Pharmaceuticals Inc. - Dallas TX
International Classification:
C07D 225/04 A61K 31/495 A61P 31/04
US Classification:
514250, 540453, 540457
Abstract:
Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.
(R/S) Rifamycin Derivatives, Their Preparations And Pharmaceutical Compositions
Charles Z. Ding - Plano TX, US Zhenkun Ma - Dallas TX, US Jing Li - Dallas TX, US Susan Harran - Dallas TX, US Yong He - Arlington TX, US Keith P. Minor - Dallas TX, US In Ho Kim - Lewisville TX, US Jamie C. Longgood - Carrollton TX, US Yafei Jin - Dallas TX, US Keith D. Combrink - Fort Worth TX, US
Assignee:
Cumbre Pharmaceuticals Inc. - Dallas TX
International Classification:
C07D 498/08 A61K 31/4709 A61P 31/04
US Classification:
514306, 540458, 548138, 548208
Abstract:
Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C-C) forms):.
Zhenkun Ma - Dallas TX, US Jing Li - Dallas TX, US Susan Harran - Dallas TX, US Yong He - Arlington TX, US Keith P. Minor - Dallas TX, US In Ho Kim - Lewisville TX, US Charles Z. Ding - Plano TX, US Jamie C. Longgood - Carrolton TX, US Yafei Jin - Dallas TX, US Keith D. Combrink - Fort Worth TX, US
Assignee:
Cumbre Pharmaceuticals Inc. - Dallas TX
International Classification:
C07D 498/08 A61K 31/4709 A61P 31/04
US Classification:
51425217, 514278, 514306, 540459
Abstract:
Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C-C) forms):.
Rifamycin Imino Derivatives Effective Against Drug-Resistant Microbes
Charles Z. Ding - Plano TX, US Yafei Jin - Dallas TX, US Jamie C. Longgood - Carrollton TX, US Zhenkun Ma - Dallas TX, US Jing Li - Dallas TX, US In Ho Kim - Flower Mound TX, US Keith P. Minor - Dallas TX, US Susan Harran - Dallas TX, US
The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.
Rifamycin Derivatives Effective Against Drug-Resistant Microbes
Zhenkun Ma - Dallas TX, US Yafei Jin - Dallas TX, US Jing Li - Dallas TX, US Charles Z. Ding - Plano TX, US Keith P. Minor - Dallas TX, US Jamie C. Longgood - Carrollton TX, US In Ho Kim - Flower Mound TX, US Susan Harran - Dallas TX, US Keith Combrink - Fort Worth TX, US Timothy W. Morris - Coppell TX, US
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
Rifamycin C-11 Oxime Derivatives Effective Against Drug-Resistant Microbes
The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.
Rifamycin C-11 Oxime Cyclo Derivatives Effective Against Drug-Resistant Microbes
Jing Li - Dallas TX, US Zhenkun Ma - Dallas TX, US
Assignee:
Cumbre Pharmaceuticals Inc. - Dallas TX
International Classification:
C07D 498/18 A61K 31/395 A61K 31/535 A61P 31/04
US Classification:
5142295, 51425308, 514277, 540456
Abstract:
The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.
Winston Salem Baptist Medical Center IM Medical Ctr Blvd Jane Way Tower 4 7 Floor, Winston Salem, NC 27157 3367163182 (phone), 3367165168 (fax)
Education:
Medical School Hebei Med Univ, Shi Jiazhuang City, Hebei, China Graduated: 1996
Procedures:
Bone Marrow Biopsy
Languages:
English Spanish
Description:
Dr. Li graduated from the Hebei Med Univ, Shi Jiazhuang City, Hebei, China in 1996. She works in Winston-Salem, NC and specializes in Internal Medicine. Dr. Li is affiliated with Wake Forest Baptist Medical Center.
Dr. Li graduated from the Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) in 1982. She works in Irvine, CA and specializes in Family Medicine and Acupuncturist. Dr. Li is affiliated with St Joseph Hospital Of Orange.
Foster City, CA12 years of broad experience in Pharmaceutical and Biotech industry:
Commercial Strategy / Strategic Marketing: Product Commercialization and Launch
... 12 years of broad experience in Pharmaceutical and Biotech industry:
Commercial Strategy / Strategic Marketing: Product Commercialization and Launch
Product Management and Pharmaceutical Sales
Strategic Planning & Business Development: M & A and In-licensing Assessment
Matrix...